Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer
Open Access
- 21 July 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 91 (14), 1241-1247
- https://doi.org/10.1093/jnci/91.14.1241
Abstract
BACKGROUND: Approximately 2.0%-2.5% of Ashkenazi Jewish women carry one of three founding mutations in the BRCA1 and BRCA2 genes, and each mutation is associated with a high lifetime risk of invasive breast cancer. We investigated the extent to which these three mutations contribute to breast cancer incidence in the Ashkenazi Jewish population. METHODS: We ascertained 457 Jewish women with prevalent cases of breast cancer who were unselected for age or family history of the disease; 412 of these women were tested for the three founder mutations (case patients). Control subjects consisted of 360 non-Jewish women with breast cancer (control patients) and 380 healthy Jewish women with no history of cancer (control subjects). RESULTS: Mutations were found in 48 (11.7%) of 412 Jewish case patients. Forty-six of 48 mutations occurred in women with early-onset breast cancer (<50 years) or a history of ovarian or early-onset breast cancer in a first-, second-, or third-degree relative. The estimated penetrance to age 70 years for breast cancer was 59.9% for the BRCA1 gene mutations and 28.3% for the BRCA2 gene mutation. Compared with Jewish control subjects, the relative risk (RR) of breast cancer for first-degree relatives of mutation carriers was 5.16 (95% confidence interval [CI] = 3.14-8.48), but risk was also increased for relatives of noncarriers (RR = 1.66; 95% CI = 1.18-2.33). The RR of prostate cancer for first-degree relatives of Jewish case patients was 3.36 (95% CI = 1.49-7.56). CONCLUSIONS: Approximately 12% of breast cancers in the Ashkenazi Jewish population are attributable to mutations in the BRCA1 or BRCA2 gene. Genetic testing may be useful when Jewish women with breast cancer are diagnosed before age 50 years or have a close relative with ovarian or early-onset breast cancer. An association between breast and prostate cancers was observed in our study population.Keywords
This publication has 26 references indexed in Scilit:
- The Kin-Cohort Study for Estimating PenetranceAmerican Journal of Epidemiology, 1998
- The Risk of Cancer Associated with Specific Mutations ofBRCA1andBRCA2among Ashkenazi JewsNew England Journal of Medicine, 1997
- The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%Nature Genetics, 1996
- Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2Nature Genetics, 1996
- Germline BRCA1 185delAG mutations in Jewish women with breast cancerThe Lancet, 1996
- Jewish religion and risk of breast cancerThe Lancet, 1996
- Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancerNature Genetics, 1996
- Mutation analysis of the BRCA2 gene in 49 site–specific breast cancer familiesNature Genetics, 1996
- Germ-LineBRCA1Mutations in Jewish and Non-Jewish Women with Early-Onset Breast CancerNew England Journal of Medicine, 1996
- The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individualsNature Genetics, 1995